South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology. The agreement involves access to ALT-B4 (berahyaluronidase alfa), a recombinant human hyaluronidase created with Alteogen’s Hybrozyme platform. Under the agreement, Alteogen is set to receive an upfront payment and could earn additional amounts through development, regulatory, and sales milestone payments. Developed since Alteogen’s founding in 2008, its Hybrozyme technology enables subcutaneous delivery of medicines that are typically administered intravenously. In March 2025, AstraZeneca entered an exclusive licence agreement with bio-platform company Alteogen, involving the latter’s hyaluronidase utilising Hybrozyme platform technology, ALT-B4, to develop subcutaneous formulations of several oncology assets.